New: NCI-funded clinical trial search
Mednet Logo

Is bilateral hearing loss requiring hearing aids an absolute or relative contraindication for neoadjuvant cisplatin in MIBC?

Galsky criteria are for metastatic disease, can they be relaxed in localized MIBC setting given curative intent of therapy?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Washington School of Medicine
Answered on

For this “curative intent” neoadjuvant therapy setting, a detailed discussion with the patient is very helpful and should include the pros/cons of cisplatin based chemotherapy based on phase 3 trials data and a meta-analysis showing OS benefit as well as possible side effects, including hearing loss. Referral to an audiologist and close monitoring can also help. Would consider it a relative contraindication and an opportunity for shared/informed decision-making with the patient taking into accou...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Medical Oncology · Lewisburg Cancer Center | Evangelical Hospital
Answered on · Updated on

Currently, the most effective mechanism to manage ototoxicity is to identify patients at risk and implement programs to support ongoing monitoring. There is a need for improved education and collaboration between otolaryngology, audiology, and medical oncology to develop and promote effective ototoxicity monitoring programs. Even if ototoxicity cannot be prevented in some patients, providing treating oncologists with a timely opportunity to alter therapy or providing patients with support, guida...

Join for free or sign in to see the full answer